Kornimate/medical-research-clean huggingface dataset:
e-hero: ending the hiv epidemic in rural oklahoma

Conditions: Human Immunodeficiency Virus (HIV)

Summary: the goal of this study is to increase hiv and syphilis testing and linkage to care, increase condom use, and promote prep uptake among sexual minority men (smm) and american indian (ai) men in rural oklahoma, a state that is an ending the hiv epidemic (ehe) priority state. the proposed supplement aims to: refine our preliminary intervention strategy in partnership with a community advisory board (cab) and rural peer mentors, and to assess feasibility, acceptability, and preliminary impact of the e-hero intervention.

in the u.s., incidence rates of hiv and sexually transmitted infections (stis) are disproportionately high among gay, bisexual, and other men who have sex with men-referred to herein as sexual minority men (smm)-compared to men who have sex with women only. similarly, rates of hiv infection have increased among american indian (ai) men. this is a two-group, active-control rct of the online e-hero intervention. participants (100 smm; 100 ai men) will be randomized into two groups in equal proportions. this study evaluates two versions of an online sexual health intervention. the e-hero intervention includes 10 modules, totaling approximately 2.5 hours of content. across these modules, e-hero uses diverse delivery methods (e.g., videos, interactive games) to address hiv and sti knowledge, behavioral skills, hiv and sti testing intention, and instill self-efficacy to primary and secondary prevention behaviors. those in the intervention condition will also engage in three virtual group discussion sessions with peer mentors. the control condition contains the same number of modules as e-hero. the control condition contains the same number of modules as e-hero. the control arm reflects hiv and sti information that is currently available on many websites, with the aim to understand how the cultural tailoring of e-hero modules improves upon information that is readily available online.

Eligibility criteria:
inclusion criteria: * provide signed and dated informed consent form * be willing and able to follow study procedures and instructions and be available for the duration of the study * be between 17 and 29 years of age * be american indian or a gay, bisexual, or other man who has sex with men. american indian status is self-identified-no tribal enrollment verification will be required. * be a resident of oklahoma, in a rural identified county exclusion criteria: * anything that would place the individual at increased risk or preclude the individual's full compliance with, or completion of, the study. * hiv diagnosis

Keywords: sexual and gender minorities; american indian; hiv testing
remimazolam total intravenous anesthesia under analgesia nociception index-guidance

Conditions: Knee Osteoarthritis; Total Knee Arthroplasty; Remimazolam

Summary: the investigators hypothesized that intraoperative opioid consumption would be different between remimazolam and propofol if the ani-guided remifentanil continuous infusion rate was adjusted when the depth of anesthesia was maintained at similar depths with remimazolam or propofol under total intravenous anesthesia. the purpose of this study is to compare the intraoperative remifentanil requirement in patients undergoing total knee arthroplasty when the intraoperative remifentanil dose adjustment was performed under the ani guidance while maintaining a similar depth of anesthesia with remimazolam or propofol.


Eligibility criteria:
inclusion criteria: 1. patients 19\~80 years of age who are expected to elective total knee arthroplasty under general anesthesia 2. asa ps 1-3 exclusion criteria: 1. second total knee arthroplasty under a prior plan of staged total knee arthroplasty, both 2. previous hepatectomy or liver transplant 3. estimated glomerular filtration rate \< 30 ml/min/1.73m2 4. patients with moderate or more hepatic impairment (ast/alt is more than 2.5 times the upper limit of normal) 5. uncontrolled hypertension (systolic blood pressure \> 160mmhg) 6. acute narrow angle glaucoma 7. myasthesia gravis 8. known allergy to the drugs included in the study 9. cardiac arrhthmia (non-sinus rhythm) 10. taking drugs that affect the autonomic nervous system of diabetes 11. psychiatric or neurologic disease (major depression disorder, dementia or cerebral infarction) 12. history of drug or alcohol abuse
using mobile phone short message service (sms) reminders to enhance appointment attendance in dm patients

Conditions: Appointments and Schedules; Diabetes Mellitus, Type 2

Summary: a randomized controlled trial of patients with type 2 diabetes mellitus with multiple appointments into short message service group and control group. the attendance rate of these two groups of patients will be compared.

the main objective of this study is to evaluate the appointment attendance rate using sms reminder of nurses and allied health appointments for diabetic patients, when compared to conventional telephone reminder and no reminder. we also aim at determine the factors associated with appointment attendance. finally, we will also survey patients' acceptance and satisfaction to the sms service. this is a single blind randomization study. it will be carried out in ha kwai chung general outpatient clinic. the primary outcome of this study is to evaluate the attendance rate of each individual doctor, nurses and allied health clinic appointments for diabetic patients, as well as their overall attendance rates: 1. diabetes complication screening clinic (opas dmcs/rdna) 2. diabetes nurse intervention clinic (opas dmic/rdni) 3. dm nurse group (opas rdng) 4. dietitian counselling (opas dc/dg) 5. physiotherapy (opas ptc/ptg) 6. diabetes doctor session (opas rdr) 7. retino photo assessment (opas rdo) 8. blood taking appointment (opas labt) the secondary outcomes are: * acceptance rate of sms reminder vs telephone reminder vs no reminder * factors associated with acceptance of sms 1. personal parameters: age, sex, educational level, occupation, mobile phone models, habit of using mobile phone service 2. disease parameters: number and types of comorbidity, disease control (by biochemical markers) 3. quality of life (by sf-6d) * reported adverse effects of the reminder system * chang in biochemical markers (bmi, hba1c, ldl-c level) 6-9 months later subjects who agreed to participate in this study will first receive a survey on the acceptance of sms service. for those agree to receive sms reminder, they will be randomized to: 1. an sms remind them to come for scheduled clinic appointment 24-72 hours before, or 2. usual care with no reminder / telephone reminder.

Eligibility criteria:
inclusion criteria: * with diagnosis of type 2 diabetes * have more than 1 clinic services appointment under ramp-dm programme: (e.g. blood taking, diabetic nurse individual counselling, group education, diabetic complication screening, retinal photo assessment, dietician counselling, etc) exclusion criteria: 1. cannot read or receive appointment schedule on mobile phone 2. do not speak cantonese/english or read chinese/english 3. mentally incapacitated 4. pregnant women

Keywords: short message service appointment reminder attendance rate
coronary artery assessement by tee in congenital heart disease

Conditions: Congenital Heart Disease

Summary: this study aims to establish normal coronary artery pulse doppler flow patterns and velocities using transoesophageal echocardiography (tee) in patients with a variety of congenital heart disease. this will be accomplished by performing pre-operative and intra-operative tees on up to 250 patients undergoing surgery for congenital heart disease.

little is known about coronary artery flow patterns in children. invasive and non invasive studies in normal children have demonstrated that coronary artery flow velocities decrease with age and therefore heart rate. 'normal' flow velocities in the left coronary artery are usually accepted between 0.3-0.6m/sec depending on age of the patient. less is known about coronary flow patterns and velocities in patients with congenital heart disease. in addition the effects of coronary artery bypass and altered loading conditions may affect coronary flow patterns and velocities and in theory alter short and long term outcomes. this study hopes to is to establish normal coronary artery pulse doppler flow patterns and velocities using transoesophageal echocardiography (tee) in patients with a variety of congenital heart disease.

Eligibility criteria:
inclusion criteria: * all patients undergoing surgical repair of congenital heart lesions at the hospital for sick children between may 2017 and may 2018. exclusion criteria: 1. patients with hypoplastic left heart syndrome undergoing norwood operation or hybrid procedure 2. patients who have undergone heart transplantation. 3. patients were transoespphageal echocardiography is contraindicated (less than 3kg, recent upper gastrointestinal surgery). 4. operations where tee is not routinely indicated (patent ductus arteriosus ligation, aortic coarctation repair via a thoracotomy, vascular ring ligations). 5. patients whose primary reason for surgery is coronary artery stenosis

Keywords: transesophageal echocardiography
riluzole in huntington's disease

Conditions: Huntington Disease

Summary: primary objective: * the primary objective of the study is to establish that riluzole slows down (1) the decrease in total functional capacity (tfc), (2) the increase of the motor score of the unified huntington's disease rating scale (uhdrs) as well as (3) the increase of a combined score of these. secondary objectives: secondary objectives are to assess * changes in the other uhdrs subscales * the number of patients who need antichoreic treatment and the time until this treatment has to be initiated * the safety/tolerability of riluzole in huntington patients


Eligibility criteria:
inclusion criteria: * clinical diagnosis of huntington's disease and cag repeat length of 36 or more * uhdrs motor score of at least 5 points * uhdrs tfc score of at least 8 points, i.e. patients must be independently ambulatory and must not require nursing care * females require a negative blood pregnancy test at inclusion exclusion criteria: * any forms of chorea other than huntington's disease * patients on antichoreic treatment within one month prior to entry or foreseen to require such treatment within the first 3 months after randomization (antichoreic medication is prohibited during entire study) * other unacceptable prior/concomitant medications * uncontrolled major psychiatric disorders, in particular uncontrolled major depression (dsm iv definition) * drug or alcohol dependence and/or abuse (dsm iv definition) within the past 6 months * any other concomitant disease with a reasonable possibility to interfere with the study * females who are breast-feeding, not sterilized, at least one year postmenopausal or don't use an adequate contraceptive method for at least one month prior to and during study participation * participation in another clinical study with any investigational drug within 30 days prior to study screening * prior exposure to riluzole * alt and/or ast and/or total bilirubin levels greater than 1.5 times the upper limits of normal range, or hepatic disease other than gilbert's disease * creatinine serum concentrations above 200 µmol/l (resp. 2,3 mg/dl) or hematology parameters as follows: hemoglobin smaller 11 g/dl for males resp. smaller 10 g/dl for females, or white blood cell smaller 3,5 x 10000000000/l
evaluation of pancreatic duct stenting in patients with pancreatic pseudocysts.

Conditions: Chronic Acute Pancreatitis

Summary: the disruption of the pancreatic duct seems to be a major cause pseudocyst formation and persistence in patients suffering from acute/chronic pancreatitis. no prospective randomized studies have been conducted on the influence of pancreatic duct stenting for the patients' benefits and recurrence rates. the aim fo this study is therefore to evaluate prospectively in a randomized, controlled fashion in patients wit pancreatic pseudocysts, wether pancreatic duct stenting of a disrupted pancreatic duct is beneficial in terms of quicker clinical recovery and avoidance of recurrence of pancreatic pseudocysts.


Eligibility criteria:
inclusion criteria: * pancreatic pseudocyst, at least 6 cm in diameter * symptomatic pancreatic pseudocyst * increasing size of pancreatic pseudocyst within 6 weeks exclusion criteria: * pregnancy * age less than 18 years * postoperative status preventing access to papilla * allergy to contrast preventing from erp * missing informed consent to study * ptt above 1.5 times of normal, unless substituted * platelet count less than 50.000/µl, unless substituted * pancreatic ascites or fistula * life expectancy less than 2 years * percutaneously drained cysts are not part of the study

Keywords: disrupted duct pancreatic pseudocysts
efficacy of bifidobacterium longum 35624 on the quality of life of ibs patients with different symptom severity

Conditions: Irritable Bowel Syndrome

Summary: the main objective of this observatory is to evaluate the effect of bifidobacterium longum 35624 on the quality of life of ibs patients having different subtypes of transit pattern and different level of symptom severity

this observatory evaluate the effect of bifidobacterium longum 35624 on the quality of life of ibs patients having different subtypes of transit pattern and different level of symptom severity, after a one-month treatment with bibidobacterium longum 35624, 1x10\^9 cfu/capsule, 1 capsule/day.

Eligibility criteria:
inclusion criteria: * male or female, at least 18 years of age * gastroenterology consultation for an irritable bowel syndrome according to rome iv criteria * having received a first prescription of bifidobacterium longum 35624 during the consultation (independently of participation in the observatory) * informed and having declared his/her non-opposition to the study. exclusion criteria: * not having a good enough command of reading and comprehension of the french language to correctly complete the questionnaires and the notebook * having already taken bifidobacterium longum 35624 * having received probiotics or antibiotics within 2 weeks previous * having started within the last 7 days a treatment that can interfere with the investigator's evaluation of the investigational product under investigation * participant in another trial * pregnant or breastfeeding women * being under guardianship or curator. * not having a good enough command of reading and comprehension of the french language to correctly complete the questionnaires and the notebook
randomized trial of two antimalarial treatments for clearing low density p.falciparum parasitaemia in sudan

Conditions: Plasmodium Infections

Summary: in areas of seasonal malaria transmission, treatment of carriers of malaria parasites, whose parasitaemia persists at very low levels throughout the dry season, could be a useful strategy for malaria control in areas with a short transmission season. we did a randomized trial to compare two regimens for clearance of low level parasitaemia in the dry season.

104 individuals with low density plasmodium falciparum infection detected by polymerase chain reaction (pcr) were randomized to receive sulfadoxine-pyrimethamine and three daily doses of artesunate (sp+as) or sp+as and a dose of primaquine (sp+as+pq), and were followed up for 14 days during the transmission-free season in eastern sudan. subjects were visited on days 3, 7 and 14 after the start of treatment to record any adverse events and to detect p.falciparum using pcr. pcr positive samples were tested for gametocytes using rt-pcr. packed cell volume was measured on days 7 and 14.

Eligibility criteria:
inclusion criteria: * infection with p.falciparum detected by pcr exclusion criteria: * pregnancy * severe anaemia * fever or other signs of illness * history of allergy to sulfa drugs * presence of other species of plasmodium detected by microscopy

Keywords: malaria subpatent parasitaemia dry season primaquine plasmodium falciparum infection detected by pcr
accuracy of robotically assisted cranial biopsies

Conditions: Intracranial Neoplasm

Summary: this is an observational post-market study determining biopsy accuracy in a clinical environment using cirq® robotic alignment module cranial. the goal is to determine whether the robotic procedure to be examined can achieve a clinically acceptable value of at least 90% in terms of diagnostic yield.

the goals of the project are to determine the accuracy of cirq® robotic alignment module cranial navigated biopsy procedures, automatic image registration accuracy within the workflow, and compatibility of cirq® robotic alignment module cranial in the clinical workflow. patients will undergo cranial biopsies according to standard of care using released products within their intended use with the exception that the accuracy of the biopsy needle will be measured using a specific intraoperative workflow.

Eligibility criteria:
inclusion criteria: * intracranial lesion and the indication for a diagnostic stereotactic biopsy validated by the neurosurgical staff * ability to consent to the procedure exclusion criteria: * pregnancy * contraindications on narcosis, operation, ct scan, mri scan and/or gadolinium contrast agent
an exploratory study to evaluate immune determinants of the response to adoptive cell therapy (act) in solid and hematologic tumors

Conditions: Solid Tumor, Adult; Solid Tumor, Childhood; Hematologic Cancer

Summary: this is a study to explore the phenotypic and transcriptional changes of different cellular components in the tumor following the injection of somatic cell therapy drugs. the second objective is to explore phenotypic and transcriptional changes of different cellular components in blood and bone marrow following injection of somatic cell therapy drugs.then correlate the phenotypic and transcriptional profile of different tumor, blood and bone marrow immune populations with clinical response and/or toxicity. and to finish this study is designed in order to identify a phenotypic, transcriptional and epigenetic profile of intra-tumoral adoptive cells and correlate this profile with clinical response and/or toxicity.


Eligibility criteria:
inclusion criteria: * patient affiliated to a social security regimen * tumor lesion accessible to core biopsies * patient who is fully informed, able to comply with the protocol and who signed the informed consent * pediatric patients \> than 2 years old can be included * no restriction about the eastern cooperative oncology group (ecog) status exclusion criteria: * coagulation abnormality prohibiting a biopsy (but patients can still give their consent for blood and bone marrow samples). * tumor lesion not accessible to core biopsies. * pregnant or nursing women cannot participate in this study.
electrical stimulation of the quadriceps and diaphragm in critically ill patients

Conditions: Critical Illness Myopathy; Respiration, Artificial

Summary: subjects in mv will be included, divided into 3 groups: (a) control group (cg), (b) stimulation of quadriceps (quadriceps group - qg), (c) stimulation of diaphragm (diaphragm group - dg). the qg and dg patients will receive consecutive daily electrical stimulation sessions at specific points from the first day of randomization until icu discharge. respiratory and peripheral muscle strength, mv time, length of hospitalization and functional independence score (the functional status score-icu) will be recorded.

objective: evaluate the effectiveness of the neuro muscular electrical stimulation therapy in quadriceps versus diaphragm subjects on mechanical ventilation (mv). subjects in mv will be included, divided into 3 groups: (a) control group (cg), (b) stimulation of quadriceps (quadriceps group - qg), (c) stimulation of diaphragm (diaphragm group - dg). the qg and dg patients will receive consecutive daily electrical stimulation sessions at specific points from the first day of randomization until icu discharge. respiratory and peripheral muscle strength, mv time, length of hospitalization and functional independence score (the functional status score-icu) will be recorded.

Eligibility criteria:
inclusion criteria: * age of 18 years or more * 24 hours of mv or more exclusion criteria: hemodynamic instability, pregnancy, body mass index(bmi) \>35 kg/m2, history of neuromuscular disease at admission, brain death, diseases with systemic vascular involvement, bone fractures, use of an internal or external fixator, skin lesions, end-stage cancer, use of pacemakers, spinal injuries, or inability to receive an medical research council score because of the cognitive state.

Keywords: electric stimulation intensive care units mechanical ventilation ventilator weaning
a registry for patients taking uptravi

Conditions: Pulmonary Arterial Hypertension

Summary: this is a us multi-center, prospective, real world, observational drug registry enrolling patients actively treated with uptravi. participating patients will be followed prospectively for a maximum of 18 months from the date of enrollment into the registry.


Eligibility criteria:
inclusion criteria: * signed patient informed consent form (icf). * patients ≥ 18 years of age at time of uptravi initiation, and * patients who initiate uptravi: * at enrollment, or * less than or equal to 60 days prior to enrollment and have a documented titration regimen (defined as all documented dose changes including, but not limited to: starting dose and dates and highest tolerated dose and dates) exclusion criteria: * patients previously exposed to uptravi treatment during a clinical trial. * patients that previously discontinued uptravi for any reason, prior to study enrollment (discontinuation defined as an interruption of therapy greater than or equal to 30 days). * patients enrolled in a blinded clinical trial or in a clinical trial involving an unapproved drug.
laparoscopic lateral mesh suspension for pelvic organ prolapse

Conditions: Pelvic Organ Prolapse; Pelvic Floor Prolapse

Summary: this study is aimed to share our clinical experience in an uterine-preserving laparoscopic lateral suspension of apical prolapses with mesh operation after minor modifications in technique. transperineal ultrasonography and several questionnaires are used for objective and subjective outcomes.

vaginal length, bladder neck mobility and pelvic floor biometry with anteroposterior hiatal diameter and pelvic organ descent measurements are measured by transperineal ultrasonography to assess anatomic success in the preoperative and at postoperative 18th months if available. female sexual function index (fsfi), michigan incontinence severity index (m-isi), prolapse quality of life questionnaire (pqol), pelvic organ prolapse symptom score (pop-ss) and visual analog score (vas) are used to assess subjective success in the preoperative and at postoperative 18th months if available. ,

Eligibility criteria:
inclusion criteria: * \>18 years old symptomatic women with pelvic organ prolapse needing surgery. * patients who are not comfortable with using or refusing pessary * refusing sacrocolpopexy due to its serious surgical risk exclusion criteria: * patients who prefer sacrocolpopexy * any cue for gynecologic oncological condition * patients who approves le fort colpocleisis among who does not have any sexual intercourse

Keywords: pelvic organ prolapse translabial ultrasound transperineal ultrasound lateral mesh suspension descensus uteri laparoscopic pelvic organ prolapse repair